| |NOVEMBER 20259SALESFORCE UNVEILS AI-POWERED AGENTFORCE FOR LIFE SCIENCESBAYER'S LYNKUET GETS FDA NOD FOR MENOPAUSAL HOT FLASHESSalesforce India has introduced Agentforce Life Sciences for Customer Engagement, expanding its Agentforce Life Sciences portfolio with an innovative, agent-first solution designed to transform how life sciences organizations connect with healthcare professionals (HCPs).The launch addresses a major challenge within the industry: today's physicians face an overwhelming information burden 75% more data per drug than a decade ago--yet only about one-third feel adequately supported. Many continue to report being overwhelmed by excessive outreach from pharmaceutical and medical device companies.In response, Agentforce Life Sciences leverages digital labor to deliver more personalized, meaningful interactions, reducing noise while helping bridge critical care gaps. The solution redefines how drugs and medical devices are discovered, approved, accessed, and administered, empowering professionals to focus on the human side of healthcare.Built natively on the Salesforce platform, Agentforce Life Sciences for Customer Engagement extends beyond traditional CRM systems by offering a conversational, consumer-grade experience backed by enterprise-level security.It enables representatives to maximize their limited time with busy practitioners through features like voice-dictated notes, advocacy scoring, radio-style briefings, and concise account summaries.With seamless, 24/7 access to critical insights, life sciences teams can engage more effectively and enhance patient outcomes.Mankiran Chowhan, managing director - sales at Salesforce India said, "India's life sciences sector is scaling at an incredible pace, in parallel, the engagement model with doctors needs to keep pace. With Agentforce Life Sciences, we're fundamentally upgrading that model.We're moving from high-volume, low-impact communication to intelligent, trusted collaboration. This allows companies to serve the immense Indian market more effectively and helps empower healthcare professionals to make faster, better-informed decisions for their patients. For doctors, it means getting the right insights to better treat their patients. And for India, it means closing the gap between medical innovation and patient access." POThe U.S. Food and Drug Administration (FDA) has given approval to Lynkuet (elinzanetant), Bayer's dual neurokinin (NK) receptor antagonist that is not accompanied by the use of hormones and is the first treatment of moderate to severe vasomotor symptoms (VMS), i.e., hot flashes, connected with menopause, to be used.Lynkuet works by blocking the NK1 and NK3 receptors on KNDy neurons, which leads to the inhibition of Substance P and Neurokinin B. At the same time, the brain's thermoregulatory pathways that cause the frequency and intensity of hot flashes are normalized as a result of the regulation by KNDy neurons.The U.S. Food and Drug Administration (FDA) approval is derived from the Phase III OASIS 1, OASIS 2, and OASIS 3 clinical trials that tested the efficacy and safety profile of Lynkuet. In these pivotal studies, elinzanetant reduced the occurrence and also the intensity of hot flashes significantly by weeks 4 and 12 when comparing the treated and placebo groups with the continuation of the benefits and safety being confirmed during the 52 weeks of the OASIS 3 trial."This approval is a major milestone in Bayer's women's health portfolio over the last 100 years," says Christine Roth, Executive Vice President, Global Product Strategy and Commercialization at Bayer. "With Lynkuet around, a hormone-free choice is available to women who want tailored menopause care."Lead investigator, Dr JoAnn Pinkerton of UVA Health, shared that the therapy presents an effective, tolerable, and first-line approach for women suffering from hot flashes and, thus, has the potential to significantly raise the quality of life during menopause. PO
< Page 8 | Page 10 >